Chiba M, Schwab A J, Goresky C A, Pang K S
Faculty of Pharmacy, University of Toronto, Ontario, Canada.
Hepatology. 1998 Jan;27(1):134-46. doi: 10.1002/hep.510270122.
The hepatocellular entry of 4-methylumbelliferyl sulfate (4MUS) a highly ionized and highly bound anion capable of futile cycling, was examined in the single-pass albumin-free perfused rat liver preparation. Desulfation of 4MUS to 4-methylumbelliferone (4MU) was verified in vitro to be a low-affinity, high-capacity process (Km = 731 micromol/L; Vmax = 414 nmol min(-1) g(-1) liver). With 4MUS given to the perfused rat liver, sulfation of 4MU, the formed metabolite, was attenuated in the presence of 2,6-dichloro-4-nitrophenol (DCNP), a sulfation inhibitor, and when sulfate ion was substituted by chloride ion. 4MU sulfation, being a high-affinity system, was reduced most effectively at the lowest 4MUS concentration (15 micromol/L) used, evidenced by the increased (24%) net hepatic extraction ratio of 4MUS and reduced utilization (72%) of infused tracer 35SO4(2-) by 4MU for 4MU35S formation. Single-pass multiple indicator dilution (MID) studies were thus conducted under identical conditions (DCNP and absence of inorganic sulfate), with injection of [3H]4MUS and a set of noneliminated vascular and cellular reference indicators into the portal vein (prograde) or hepatic vein (retrograde), against varying background bulk concentrations of 4MUS (5 to 900 micromol/L). The steady-state removal rate of 4MUS and formation rates of 4MU and its glucuronide conjugate (4MUG) were not altered with perfusion flow direction, suggesting the presence of even or parallel distributions of 4MUS desulfation and 4MU glucuronidation activities. When the outflow dilution profile of [3H]4MUS was evaluated with the barrier-limited model of Goresky, a slight red cell carriage effect was found for 4MUS. The permeability surface area product for cellular entry for prograde showed a dramatic concentration-dependent decrease (from 0.13 to 0.01 mL sec(-1) g(-1), or 7.4 to 0.56 times the blood perfusate flow rate) and was resolved as saturable and nonsaturable components, while data for retrograde were more scattered, varying from 2.8 to 1 times the blood perfusate flow rate. Efflux (coefficient = 0.0096 +/- 0.0024 and 0.0088 +/- 0.0062 mL sec(-1) g(-1), respectively) was relatively insensitive to concentration and flow direction. The same was observed for the removal capacity for metabolism and excretion (sequestration coefficient: for prograde, 0.0056 +/- 0.0017 mL sec(-1) g(-1); for retrograde, 0.0056 +/- 0.003 mL sec(-1) g(-1)). The decrease in the apparent partition coefficient (ratio of 4MUS concentration estimated in tissue to unbound plasma concentration) and the increase in relative throughput component with concentration further substantiate the claim on the presence of concentrative processes at the sinusoidal membrane.
在无白蛋白单通道灌注大鼠肝脏制备模型中,研究了高度离子化且能进行无效循环的高结合性阴离子硫酸4 - 甲基伞形酮(4MUS)的肝细胞摄取情况。体外实验证实,4MUS脱硫酸生成4 - 甲基伞形酮(4MU)是一个低亲和力、高容量的过程(米氏常数Km = 731微摩尔/升;最大反应速度Vmax = 414纳摩尔·分钟⁻¹·克⁻¹肝脏)。给灌注大鼠肝脏给予4MUS后,在硫酸化抑制剂2,6 - 二氯 - 4 - 硝基苯酚(DCNP)存在时,以及用氯离子替代硫酸根离子时,生成的代谢产物4MU的硫酸化作用减弱。4MU硫酸化是一个高亲和力系统,在所使用的最低4MUS浓度(15微摩尔/升)时,其受到的抑制最为有效,这表现为4MUS的肝脏净提取率增加(24%),以及4MU用于形成4MU³⁵S时对注入示踪剂³⁵SO₄²⁻的利用率降低(72%)。因此,在相同条件下(存在DCNP且无无机硫酸盐)进行了单通道多指示剂稀释(MID)研究,将[³H]4MUS以及一组未被清除的血管和细胞参考指示剂注入门静脉(顺行)或肝静脉(逆行),同时改变4MUS的背景总体浓度(5至900微摩尔/升)。4MUS的稳态清除率以及4MU及其葡萄糖醛酸结合物(4MUG)的生成率不受灌注流向的影响,这表明4MUS脱硫酸和4MU葡萄糖醛酸化活性存在均匀或平行分布。当用戈列斯基的屏障限制模型评估[³H]4MUS的流出稀释曲线时,发现4MUS存在轻微的红细胞携带效应。顺行时细胞摄取的通透表面积乘积呈现出显著的浓度依赖性下降(从0.13降至0.01毫升·秒⁻¹·克⁻¹,即血液灌注流速的7.4至0.56倍),并可分解为饱和和非饱和成分,而逆行数据则更为分散,在血液灌注流速的2.8至1倍之间变化。流出(系数分别为0.0096 ± 0.0024和0.0088 ± 0.0062毫升·秒⁻¹·克⁻¹)对浓度和流向相对不敏感。代谢和排泄的清除能力也有相同情况(滞留系数:顺行为0.0056 ± 0.0017毫升·秒⁻¹·克⁻¹;逆行为0.0056 ± 0.003毫升·秒⁻¹·克⁻¹)。表观分配系数(组织中估计的4MUS浓度与未结合血浆浓度之比)的降低以及相对通量成分随浓度的增加,进一步证实了在肝血窦膜存在浓缩过程的说法。